论文部分内容阅读
本文报道利福喷丁正常人药物动力学研究结果，健康志愿者１０人单剂口服利福喷丁粉剂及胶囊６００ｍｇ后的体内过程均符合血管外一室模型，其血药峰浓度分别为１７．４３ｍｇ／Ｌ（粉剂）和１８．３８ｍｇ／Ｌ（胶囊），达峰时间为９，７０ｈ（粉剂和）和８．２１ｈ（胶囊），消除半衰期（ｔ１／２ｋｅ）为１９．９０ｈ（粉剂）和１９．４２ｈ（胶囊），以上各项参数经统计学处理均无明显意义，胶囊的相对生物利用度为１０４．７２％，口服该药后有少量自尿中以原形排出体外，给药后２ｈ内分别排出给药量的１１．３０％（粉剂）和１１，２９％（胶囊）。
This paper reports the results of pharmacokinetics of rifapentine normal, healthy volunteers 10 single oral dose of rifapentine capsules and capsules in vivo process are in line with an extravascular 1-compartment model, the peak plasma concentrations were 17 (Powder) and 18.38 mg / L (capsule) with peak times of 9, 70h (powder and) and 8.21h (capsule) and 19.90h of elimination half-life (t1 / 2ke) And 19.42h (capsule). The above parameters were not statistically significant after treatment, the relative bioavailability of capsules was 104.72%, after oral administration of a small amount of urine excreted from the urine in vitro, after administration Within 2h were dosing 11.30% (powder) and 11,29% (capsules).